OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
+30.1%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.29%
AUM
$393M
AUM Growth
+$393M
(+1.7%)
Cap. Flow
+$2.94M
Cap. Flow
% of AUM
0.75%
Top 10 Holdings %
Top 10 Hldgs %
57.16%
Holding
48
New
12
Increased
9
Reduced
16
Closed
1
Top Buys
| 1 |
Xenon Pharmaceuticals
XENE
|
$7.01M |
| 2 |
Harrow
HROW
|
$4.5M |
| 3 |
Acadia Pharmaceuticals
ACAD
|
$4.05M |
| 4 |
Iovance Biotherapeutics
IOVA
|
$3.66M |
| 5 |
TVRD
Tvardi Therapeutics, Inc. Common Stock
TVRD
|
$3.11M |
Top Sells
| 1 |
FibroGen
FGEN
|
$9.72M |
| 2 |
Viking Therapeutics
VKTX
|
$6.53M |
| 3 |
Axogen
AXGN
|
$5.16M |
| 4 |
BFRA
Biofrontera AG American Depositary Shares
BFRA
|
$4.24M |
| 5 |
BPMC
Blueprint Medicines
BPMC
|
$3.9M |
Sector Composition
| 1 | Healthcare | 97.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Axogen
AXGN
$743M
| $47.9M | 12.19% | 1,300,000 -140,000 | -10% | -$5.16M |
|
2
Codexis
CDXS
$246M
| $30M | 7.64% | 1,750,000 | – | – |
|
|
LOXO
3
DELISTED
Loxo Oncology, Inc
LOXO
| $29.9M | 7.61% | 175,000 | – | – |
|
|
AMRN
4
Amarin Corp
AMRN
$311M
| $26M | 6.62% | 1,600,000 -150,000 | -9% | -$2.44M |
|
|
BPMC
5
DELISTED
Blueprint Medicines
BPMC
| $23.4M | 5.96% | 300,000 -50,000 | -14% | -$3.9M |
|
|
DCPH
6
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $16.3M | 4.14% | 420,000 | – | – |
|
|
PTE
7
DELISTED
PolarityTE, Inc. Common Stock
PTE
| $14.6M | 3.72% | 765,000 -35,000 | -4% | -$668K |
|
|
8
Viking Therapeutics
VKTX
$3.04B
| $14.4M | 3.66% | 825,000 -375,000 | -31% | -$6.53M |
|
|
9
FibroGen
FGEN
$47.8M
| $12.2M | 3.09% | 200,000 -160,000 | -44% | -$9.72M |
|
10
Agios Pharmaceuticals
AGIO
$2.19B
| $10M | 2.55% | 130,000 | – | – |
|
|
BOLD
11
DELISTED
Audentes Therapeutics, Inc
BOLD
| $8.91M | 2.27% | 225,000 +35,000 | +18% | +$1.39M |
|
12
Dianthus Therapeutics
DNTH
$759M
| $8.71M | 2.22% | 725,000 +175,000 | +32% | +$2.1M |
|
13
PTC Therapeutics
PTCT
$3.92B
| $8.46M | 2.15% | 180,000 | – | – |
|
|
AMAG
14
DELISTED
AMAG Pharmaceuticals, Inc.
AMAG
| $8.4M | 2.14% | 420,000 | – | – |
|
|
SBBP
15
DELISTED
Strongbridge Biopharma plc.
SBBP
| $8.39M | 2.13% | 1,730,000 -100,000 | -5% | -$485K |
|
16
Sangamo Therapeutics
SGMO
$157M
| $8.31M | 2.11% | 490,000 -15,000 | -3% | -$254K |
|
17
Fennec Pharmaceuticals
FENC
$247M
| $8M | 2.03% | 975,000 +30,000 | +3% | +$246K |
|
18
Viridian Therapeutics
VRDN
$1.5B
| $7.79M | 1.98% | 1,395,700 +195,700 | +16% | +$1.09M |
|
|
CBAY
19
DELISTED
Cymabay Therapeutics
CBAY
| $7.74M | 1.97% | 698,100 +600 | +0.1% | +$6.65K |
|
|
20
Xenon Pharmaceuticals
XENE
$2.98B
| $7.01M | 1.78% | +465,200 | New | +$7.01M |
|
21
Apellis Pharmaceuticals
APLS
$3.48B
| $6.67M | 1.7% | 375,000 +110,000 | +42% | +$1.96M |
|
22
Xencor
XNCR
$580M
| $6.14M | 1.56% | 180,000 | – | – |
|
23
Ultragenyx Pharmaceutical
RARE
$2.89B
| $6.11M | 1.55% | 80,000 | – | – |
|
24
Xoma
XOMA
$392M
| $5.62M | 1.43% | 320,000 -200 | -0.1% | -$3.51K |
|
25
Ocular Therapeutix
OCUL
$2.12B
| $5.5M | 1.4% | 800,000 -311,000 | -28% | -$2.14M |
|